Alira Health

The firm's consulting practice provides a proprietary deal-flow channel. While advising biopharma and medtech companies on clinical development, regulatory strategy, and market access, Alira Health's team identifies emerging technologies and unmet medical needs. This advisory-driven origination allows the firm to evaluate both scientific validity and commercial potential before committing capital, a distinction from venture firms reliant on inbound founder pitches or syndicate networks.

Alira Health invests primarily at seed and Series A stages in therapeutics, digital health platforms, and life sciences enabling technologies. Areas of focus include oncology, neurology, rare disease, and health IT tools, including AI-driven drug discovery. The firm may also provide revenue-based financing to commercial-stage healthcare services businesses where its advisory expertise adds operational value.

It is both. Alira Health operates an integrated model where the consulting division serves life sciences companies across the product lifecycle, and the investment arm takes direct equity positions in early-stage firms. The two functions share diligence, scientific expertise, and operator networks, making the firm a hybrid advisory-investment platform rather than a pure-play venture firm or management consultancy.

The firm concentrates on North America and Western Europe, with investment activity centered in Boston, San Francisco, and Switzerland. These regions align with the firm's consulting client base and its internal team's expertise in the US and European regulatory environments for drug and device development.

No. Alira Health does not publicly disclose assets under management or a formal fund structure. The firm invests off its own balance sheet or through undisclosed investment vehicles, and total deployment figures have not been reported in public filings or major financial publications.